A change in leadership could offer the New England Journal of Medicine the chance to re-make itself, write Retraction Watch's Adam Marcus and Ivan Oransky, at Stat News.
ProPublica writes that the New England Journal of Medicine may not be keeping up with the times.
By Turna Ray
Cepheid's Xpert MTB/RIF test received a vote of confidence for its ability to diagnose TB and rifampicin resistance in remote and resource-poor regions of the world, according to the results of a New England Journal of Medicine study.
Findings in a NEJM study this week challenged previously reported data that alleles in the CYP2C19 gene can limit how certain carriers of the polymorphisms respond to Plavix.
An opinion piece at Bloomberg discusses China's stance on genomic research.
Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.
Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.
In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.